| Amicus’s Scioderm Deal Flops as Skin Drug Fails in Phase 3 | Ben Fidler | 09/13/17 | New York |
| At Long Last, First Drug Approval in Sight for Amicus | Ben Fidler | 04/01/16 | New York |
| East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More | Ben Fidler | 09/04/15 | Boston |
| With $229M Deal, Amicus Gets a New Drug And Perhaps a Voucher | Ben Fidler | 08/31/15 | New York |
| Amicus Therapeutics Acquires Scioderm for $847,000,000 | VentureDeal | 08/31/15 | Raleigh Durham |
| Raleigh-Durham Roundup: Heat Biologics, nCino, Scioderm, & More | Frank Vinluan | 03/23/15 | Raleigh Durham |
| Raleigh-Durham Roundup: BioCryst, Scioderm, Red Hat & More | Frank Vinluan | 12/22/14 | Raleigh Durham |
| Scioderm Obtains $20,000,000 Series B Funding Round | VentureDeal | 12/19/14 | Raleigh Durham |
| Orphan Drug From Scioderm Aims to Treat Rare Skin Disease | Frank Vinluan | 10/07/14 | Raleigh Durham |
| The Biotech Startup Class of 2013: Don’t Worry, It’s a Short List | Luke Timmerman | 11/18/13 | National |
| Scioderm Garners $16,000,000 Series A Funding | VentureDeal | 04/27/13 | Raleigh Durham |
